Managing cannabis use in people with severe mental illness: What can be done?

Advances in Psychiatric Treatment

Volumn 15, Issue 1, 2009, Pages 65-71

  Atakan, Zerrin ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYTOCHROME P450 1A2; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ALCOHOLISM; ANXIETY DISORDER; CANNABIS ADDICTION; CANNABIS SMOKING; COCAINE DEPENDENCE; COGNITIVE DEFECT; COGNITIVE THERAPY; DEPRESSION; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; EXTRAPYRAMIDAL SYNDROME; FAMILY THERAPY; GROUP THERAPY; HUMAN; LONG TERM CARE; MENTAL DISEASE; MOTIVATION; NEGATIVE SYNDROME; PEER GROUP; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOSOCIAL CARE; RELAPSE; RESIDENTIAL CARE; REVIEW; RISK REDUCTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 58049132425     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.107.005140     Document Type: Review

References (34)

1. Barrowclough C, Haddock C, Tarrier N, et al (2001) Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry; 158: 1706-13.
2. Brunette MF, Mueser KT (2006a) Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder. Journal of Clinical Psychiatry; 67 (suppl 7): 10-7.
3. Brunette MF, Drake RE, Xie H, et al (2006b) Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin; 32: 637-43.
4. Buckley PF, Thompson P, Way L, et al (1994) Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. American Journal of Psychiatry; 151: 385-9.
5. Buckley PF (1998) Substance abuse in schizophrenia. A review. Journal of Clinical Psychiatry; 3 (suppl 59): 26-30.
6. Burnam MA, Morton SC, McGlynn EA, et al (1995) An experimental evaluation of residential and nonresidential treatment for dually diagnosed homeless adults. Journal of Addictive Diseases; 14: 111-34.
7. Cleary M, Hunt GE, Matheson SL, et al (2008) Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews; issue 4.
8. Denis C, Lavie E, Fatséas M, et al (2006) Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database of Systematic Reviews; issue 3.
9. Dixon L, Haas G, Weiden PJ, et al (1991) Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry; 148: 224-30.
10. Drake RE, Xie H, McHugo GJ, et al (2000) The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin; 26: 441-9.
11. Drake RE, O'Neal EL, Wallach MA (2008) A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse Treatment; 34: 123-38.
12. Faber MS, Fuhr U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clinical Pharmacology and Therapeutics; 76: 178-84.
13. Green AI (2006) Treatment of schizophrenia and co-morbid substance abuse: pharmacologic approaches. Journal of Clinical Psychiatry; 67 (suppl 7): 31-5.
14. Green AI, Burgess ES, Dawson R, et al (2003) Alcohol and cannabis use in schizophrenia. Effects of clozapine vs. Risperidone. Schizophrenia Research; 60: 81-5.
15. Green AI, Tohen MF, Hamer RM, et al (2004) First episode schizophrenia-related psychosis and substance use disorders. Acute response to olanzapine and haloperidol. Schizophrenia Research; 66: 125-35.
16. Green AI, Noordsy DL, Brunette MF, et al (2008) Substance abuse and schizophrenia: pharmacotherapeutic intervention. Journal of Substance Abuse Treatment; 34: 61-71.
17. Haddock G, Barrowclough C, Tarrier N, et al (2003) Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. British Journal of Psychiatry; 183: 418-26.
18. Harrison I, Joyce EM, Mutsatsa SH, et al (2007) Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychological Medicine; 29: 1-10.
19. James W, Preston NJ, Koh G, et al (2004) A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychological Medicine; 34: 983-90.
20. Krabbendam L, Arts B, van Os J, et al (2005) Cognitive functioning in patients with schizophrenia and bipolar disorder. A quantitative review. Schizophrenia Research; 80: 137-49.
21. Martino S, Carroll K, Kostas D, et al (2002) Dual diagnosis motivational interviewing. A modification of Motivational Interviewing for substance-abusing patients with psychotic disorders. Journal of Substance Abuse Treatment; 23: 297-308.
22. McCambridge J, Strang J (2004) The efficacy of single-session motivational interviewing in reducing drug consumption and perceptions of drug-related risk and harm among young people: results from a multi-site cluster randomized trial. Addiction; 99: 39-52.
23. McEvoy JP, Freudenreich O, Levin ED, et al (1995) Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology; 119: 124-6.
24. Miller WR, Rollnick S (2002) Motivational Interviewing: Preparing People for Change. Guilford Press.
25. Miller R, Caponi JM, Sevy S, et al (2005) The Insight-Adherence-Abstinence triad: an integrated treatment focus for cannabis-using first-episode schizophrenia patients. Bulletin of the Menninger Clinic; 69: 220-36.
26. Potvin S, Stip E, Lipp O, et al (2006) Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial. Current Medical Research and Opinion; 22: 1277-85.
27. Prochaska JO, DiClemente CC (1992) Stages of change in modification of problem behaviours. Progress in Behavior Modification; 28: 183-218.
28. Sattar SP, Bhatai SC, Petty F (2004) Potential benefits of quetiapine in the treatment of substance dependence disorders. Journal of Psychiatry and Neurosciences; 29: 452-7.
29. Schofield D, Tennant C, Nash L, et al (2006) Reasons for cannabis use in psychosis. Australian and New Zealand Journal of Psychiatry; 40: 570-4.
30. Stroup S, Appelbaum P, Swartz MS, et al (2005) Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research; 80: 1-8.
31. Weaver T, Renton A, Stimson G, et al (1999) Severe mental illness and substance misuse. Research is needed to underpin policy and services of patients with comorbidity. BMJ; 318: 137-8.
32. Ziedonis DM, Trudeau K (1997) Motivation to quit using substances among individuals with schizophrenia. Implications for a motivation-based treatment model. Schizophrenia Bulletin; 23: 229-38.
33. Zimmet SV, Strous RD, Burgess ES, et al (2000) Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder. A retrospective survey. Journal of Clinical Psychopharmacology; 20: 94-8.
34. Zullino DF, Delessert D, Eap CB, et al (2002) Tobacco and cannabis smoking cessation can lead to intoxication with clozapine and olanzapine. International Clinical Psychopharmacology; 17: 141-3.